Abbott (NYSE: ABT) has received merger control clearance from the European Commission for its acquisition of Advanced Medical Optics (AMO) through a cash tender offer for the outstanding shares of common stock of AMO. The European Commission approved the transaction without conditions.
This satisfies the condition to the tender offer related to European Commission regulatory approval and is the last regulatory approval that is a condition to the tender offer. As previously announced, the tender offer is scheduled to expire at midnight Eastern time on Tuesday, Feb. 24, 2009, unless the tender offer is extended. Consummation of the tender offer remains subject to other customary conditions, including the tender of a majority of the outstanding shares of AMO's common stock on a fully diluted basis.
As previously announced, Abbott commenced the tender offer on Jan. 27, 2009, for all of the outstanding shares of AMO common stock for $22 per share in cash. The tender offer is being made pursuant to an Offer to Purchase, dated Jan. 27, 2009, and in connection with the Agreement and Plan of Merger, dated Jan. 11, 2009, entered into by and among Abbott, Rainforest Acquisition Inc., a wholly owned subsidiary of Abbott, and AMO, which Abbott and AMO announced on Jan. 12, 2009.
About Abbott
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 69,000 people and markets its products in more than 130 countries.
Abbott's news releases and other information are available on the company's Web site at www.abbott.com.
Abbott
Abbott Receives European Commission Clearance on Acquisition of Advanced Medical Optics
- Details
- Category: Abbott
Business & Industry
- Roche's Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study
- Bayer submits EU marketing authorization application for elinzanetant to treat moderate to severe vasomotor symptoms
- Novo Nordisk launches new initiative to prevent childhood obesity in disadvantaged urban communities
- Calquence granted Priority Review in the US for patients with untreated mantle cell lymphoma
- BlueRock Therapeutics' investigational cell therapy bemdaneprocel for Parkinson's disease shows positive data at 24-months
Research & Development
- Expanding access to weight-loss drugs could save thousands of lives a year
- World-first clinical trial for treating spinal cord injury using olfactory cell nerve bridges
- Drug discovery within the patient
- Specific type of DNA could be a target of future cancer therapies
- Gene therapy automatically converts omega-6 to omega-3 fatty acids in the body
- Key molecule in wound healing identified
- Immune-based treatment gets a boost to its cancer-fighting superpowers
Conferences & Events
- New insights into T and B cells offer hope for autoimmune disease sufferers
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
Regulatory Affairs
- FDA approves new treatment for hemophilia A or B
- FDA approves nasal spray influenza vaccine for self- or caregiver-administration
- FDA approves first nasal spray for treatment of anaphylaxis
- FDA approves nonsteroidal treatment for Duchenne muscular dystrophy
- FDA approves first gene therapies to treat patients with sickle cell disease